Skip to content
Peptidepedia

How to Use PT-141 (Bremelanotide): Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration Methods

PT-141 is administered via subcutaneous injection. The FDA-approved Vyleesi product is supplied as a single-dose, pre-filled auto-injector containing 1.75 mg/0.3 mL of bremelanotide, designed for patient self-administration.

Injection Sites:

  • Abdomen (preferred)
  • Anterior thigh

Administration Procedure:

  1. Select the injection site and clean with an alcohol swab
  2. Pinch a fold of skin at the injection site
  3. Insert the auto-injector or needle at a 45 to 90 degree angle
  4. Administer the injection and hold for several seconds before withdrawing
  5. Apply gentle pressure with gauze; do not rub
  6. Rotate injection sites between doses to prevent local reactions

Timing: Administer at least 45 minutes before anticipated sexual activity. Based on pharmacokinetic data showing peak plasma concentrations at 30 to 60 minutes and maximal therapeutic effects at 2 to 4 hours, many users find injecting 1 to 2 hours before activity provides optimal results.

Intranasal formulations were explored during development but were abandoned due to blood pressure concerns. Some compounding pharmacies offer nasal spray preparations off-label, though the subcutaneous route has superior and more predictable bioavailability (approximately 100% for subcutaneous injection).

Reconstitution, Storage & Prep

Vyleesi (FDA-Approved Product):

Vyleesi is supplied as a pre-filled, single-dose auto-injector requiring no reconstitution. Store at 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit), with excursions permitted to 15 to 30 degrees Celsius.

Research-Grade Lyophilized Powder:

PT-141 is available as lyophilized powder, typically in 10 mg vials, requiring reconstitution before use.

Reconstitution Process:

  1. Allow the vial to reach room temperature
  2. Using a sterile syringe, draw the appropriate volume of bacteriostatic water (preferred for multi-use vials) or sterile water
  3. Inject the water slowly down the inside wall of the vial; do not spray directly onto the powder
  4. Gently swirl until fully dissolved; do not shake
  5. The solution should be clear and colorless; discard if cloudy or particulate matter is visible

Common Reconstitution Ratio:

  • 2 mL bacteriostatic water per 10 mg vial yields 5 mg/mL (1.75 mg = 0.35 mL / 35 units on an insulin syringe)

Storage Guidelines:

  • Unreconstituted powder: Store desiccated below -18 degrees Celsius for long-term storage; stable at room temperature for up to 3 weeks
  • Reconstituted solution: Refrigerate at 2 to 8 degrees Celsius and use within 30 days
  • Protect from light and avoid repeated freeze-thaw cycles
  • Use insulin syringes (29 to 31 gauge) for subcutaneous administration

Frequently Asked Questions

PT-141 is not FDA-approved for men, but off-label use and clinical research suggest efficacy for male erectile dysfunction and low libido. A Phase IIB trial showed positive erectile responses in 33.5% of men on bremelanotide versus 8.5% on placebo. Combination studies with PDE5 inhibitors are ongoing.

Nausea is the most common side effect, affecting approximately 40% of patients and most pronounced with the first dose. Other common side effects include flushing (20%), injection site reactions (13%), and headache (11%). PT-141 also causes a transient rise in blood pressure and reduction in heart rate.

PT-141 reaches peak plasma concentration within 30 to 60 minutes of subcutaneous injection. Most users experience onset of effects within 45 minutes, with maximal therapeutic benefit occurring 2 to 4 hours post-dose. Effects may persist for 6 to 8 hours.

PT-141 is FDA-approved as Vyleesi and available by prescription for premenopausal women with HSDD. It is also available through compounding pharmacies for off-label use. As a research peptide, it is sold in an unregulated market with variable quality and purity. It is banned in competitive sport by WADA.

The FDA-approved dose of Vyleesi is 1.75 mg administered subcutaneously at least 45 minutes before anticipated sexual activity. No more than one dose should be taken within a 24-hour period, and use should not exceed 8 doses per month.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.
  2. Clayton AH, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917.
  3. Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-38.
  4. Safarinejad MR. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-71.
  5. Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
  6. Simon JA, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(1):61-68.
  7. U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) prescribing information. NDA 210557. 2019.
  8. Dhillon S. Bremelanotide: first approval. Drugs. 2019;79(14):1599-1606.
  9. Palatin Technologies. FDA approves new drug application for Vyleesi (bremelanotide injection). Press release. June 21, 2019.
  10. World Anti-Doping Agency. The 2026 Prohibited List. WADA.
←Read the full PT-141 (Bremelanotide) guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”